{{more footnotes|date=June 2013}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477224913
| IUPAC_name =  
| image = 5-MeO-DET.svg
| width = 200px
| alt = Skeletal formula
| image2 = 5-MeO-DET molecule spacefill.png
| alt2 = Space-filling model of 5-MeO-DET

<!--Clinical data-->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 2454-70-8
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 417608
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 369669
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 342986

<!--Chemical data-->
| C=15 | H=22 | N=2 | O=1 
| molecular_weight = 246.36 g/mol
| smiles = O(c1cc2c(cc1)ncc2CCN(CC)CC)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H22N2O/c1-4-17(5-2)9-8-12-11-16-15-7-6-13(18-3)10-14(12)15/h6-7,10-11,16H,4-5,8-9H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KGDVJQQWCDDEPP-UHFFFAOYSA-N
| melting_point =  
| melting_high =  
}}
'''5-MeO-DET''' or '''5-methoxy-''N,N''-diethyltryptamine''' is a [[Psychedelics, dissociatives and deliriants|hallucinogenic]] [[tryptamine]].

==Pharmacology==
5-MeO-DET inhibits [[Serotonin reuptake inhibitor|serotonin]] reuptake with an IC<sub>50</sub> value of 2.4 µM and activates [[5-HT2A receptor|5-HT<sub>2A</sub>]] receptors with an EC<sub>50</sub> value of 8.11 nM.<ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291521-3838%28199912%2918:6%3C548::AID-QSAR548%3E3.0.CO;2-B/abstract | title=Quasi-atomistic Receptor Surrogates for the 5-HT<sub>2A</sub> Receptor: A 3D-QSAR Study on Hallucinogenic Substances | author=Meike Schulze-Alexandru | author2=Karl-Artur Kovar | author3=Angelo Vedani | journal=Quantitative Structure-Activity Relationships |date=December 1999  | volume=18 | issue=6 | pages=548–560 | doi=10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B}}</ref><ref>{{cite journal | url=http://jpet.aspetjournals.org/content/338/1/280 | title=Abuse Liability Profile of Three Substituted Tryptamines | author=Michael B. Gatch | author2=Michael J. Forster | author3=Aaron Janowsky| author4=Amy J. Eshleman | journal=Journal of Pharmacology and Experimental Therapeutics |date=April 2011  | volume=338 | issue=1 | pages=280–289 | doi=10.1124/jpet.111.179705 | pmid=21474568 | pmc=3126641}}</ref><ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/jm00190a014 | title=Serotonin receptor binding affinities of tryptamine analogs | author=Richard A. Glennon | author2=Peter K. Gessner | journal=Journal of Medicinal Chemistry |date=April 1979  | volume=22 | issue=4 | pages=428–432 | doi=10.1021/jm00190a014 | pmid=430481}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0028390811000207 | title=Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens | author=Adam L. Halberstadt | author2=Mark A. Geyer | journal=Neuropharmacology |date=September 2011  | volume=61 | issue=3 | pages=364–381 | doi=10.1016/j.neuropharm.2011.01.017 | pmid=21256140 | pmc=3110631}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/0024320568902002 | title=Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines | author=P.K. Gessner | author2=D.D. Godse | author3=A.H. Krull| author4=J.M. McMullan | journal=Life Sciences |date=March 1968  | volume=7 | issue=5 | pages=267–277 | doi=10.1016/0024-3205(68)90200-2}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/0014299988904323 | title=Indolealkylamine analogs share 5-HT<sub>2</sub> binding characteristics with phenylalkylamine hallucinogens | author=Robert A. Lyon | author2=Milt Titeler | author3=Mark R. Seggel| author4=Richard A. Glennon | journal=European Journal of Pharmacology |date=January 1988  | volume=145 | issue=3 | pages=291–297 | doi=10.1016/0014-2999(88)90432-3 | pmid=3350047}}</ref><ref>{{cite journal | url=https://link.springer.com/article/10.1007%2Fs00213-014-3557-7 | title=Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes | author=Bruce E. Blough | author2=Antonio Landavazo | author3=Ann M. Decker| author4=John S. Partilla | author5=Michael H. Baumann| author6=Richard B. Rothman | journal=Psychopharmacology |date=October 2014  | volume=231 | issue=21 | pages=4135–4144 | doi=10.1007/s00213-014-3557-7 | pmid=24800892 | pmc=4194234}}</ref>

==Effects==
Low dosages (0.5–1&nbsp;mg) are reported to produce a relaxing body high and mild [[entheogen]]ic effects. [[Alexander Shulgin|Shulgin]] reports in [[TiHKAL]] that higher dosages (1–3&nbsp;mg) can produce very unpleasant reactions.

==See also==
* [[5-MeO-DiPT]]
* [[5-MeO-DMT]]
* [[5-MeO-MiPT]]
*[[TiHKAL]]

==References==
{{reflist}}

==External links==
*[https://www.erowid.org/library/books_online/tihkal/tihkal36.shtml TiHKAL entry #36]
*[http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=36 5-MeO-DET entry in TiHKAL • info]

{{Tryptamines}}
{{Hallucinogens}}
{{TiHKAL}}
{{Serotonergics}}

[[Category:Psychedelic tryptamines]]
[[Category:Designer drugs]]


{{nervous-system-drug-stub}}